These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 2698902)

  • 1. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
    Tsouderos Y
    Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
    Tsouderos Y
    Z Kardiol; 1991; 80 Suppl 7():95-101. PubMed ID: 1792820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
    Duchene Marullaz P; Amiel M; Barbe R
    Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
    Cospite M; Dominici A
    Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
    Laurent R; Gilly R; Frileux C
    Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
    Carpentier PH; Mathieu M
    J Mal Vasc; 1998 Apr; 23(2):106-12. PubMed ID: 9608923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A double-blind study comparing the clinical efficacy of the preparation F-117 (hidrosmin) versus diosmin in the treatment of patients with peripheral venous disorders].
    Honorato Pérez J; Arcas Meca R
    Rev Med Univ Navarra; 1990; 34(2):77-9. PubMed ID: 2130425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of the pharmacodynamic activity of daflon 500 mg].
    Amiel M; Barbe R
    Ann Cardiol Angeiol (Paris); 1998 Mar; 47(3):185-8. PubMed ID: 9772947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
    Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
    Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of mesoglycan in patients with previous deep venous thrombosis and chronic venous insufficiency.
    Andreozzi GM
    Minerva Cardioangiol; 2007 Dec; 55(6):741-53. PubMed ID: 18091643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone].
    Weindorf N; Schultz-Ehrenburg U
    Z Hautkr; 1987 Jan; 62(1):28-38. PubMed ID: 3554800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daflon 500 mg: symptoms and edema clinical update.
    Ramelet AA
    Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
    Struckmann JR; Nicolaides AN
    Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
    Godeberge P
    Angiology; 1994 Jun; 45(6 Pt 2):574-8. PubMed ID: 8203790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From symptoms to leg edema: efficacy of Daflon 500 mg.
    Nicolaides AN
    Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy.
    Ting AC; Cheng SW; Wu LL; Cheung GC
    Vasc Surg; 2001; 35(6):443-7. PubMed ID: 16222383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency.
    Roztocil K; Stvrtinová V; Strejcek J
    Int Angiol; 2003 Mar; 22(1):24-31. PubMed ID: 12771852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.